How to calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight.

[1]  L. Gordon,et al.  Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation , 2006, Bone Marrow Transplantation.

[2]  S. Duffull,et al.  What is the best size descriptor to use for pharmacokinetic studies in the obese? , 2004, British journal of clinical pharmacology.

[3]  O. Ilhan,et al.  Peripheral blood stem cell apheresis for allogeneic transplants: Ibni Sina experience. , 2004, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[4]  L. Gordon,et al.  Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? , 2004, Bone Marrow Transplantation.

[5]  M. Beksac,et al.  The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation. , 2001, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[6]  A. Órfão,et al.  Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.

[7]  R. Negrin,et al.  Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  V. Diehl,et al.  Using at least 5×106/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation , 1999, Bone Marrow Transplantation.

[9]  M. Sugrue,et al.  Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight , 1999, Bone Marrow Transplantation.

[10]  O. Ilhan,et al.  The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation. , 1999, Transfusion science.

[11]  M. Beksac,et al.  A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  M. Scott,et al.  The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients , 1999, Bone Marrow Transplantation.

[13]  C. Dunbar,et al.  CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies , 1996 .

[14]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[15]  L. Schwartzberg,et al.  An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. , 1995, Blood.

[16]  R. Mick,et al.  Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. , 1995, Bone marrow transplantation.

[17]  A. Grañena,et al.  Slow response to induction chemotherapy is an indicator of poor survival after bone marrow transplantation for acute lymphoblastic leukemia. The Leukemia Working Party of the European Group of Bone Marrow Transplantation (EBMT). , 1992, Bone marrow transplantation.

[18]  C. Ireton-Jones,et al.  Actual or ideal body weight: which should be used to predict energy expenditure? , 1991, Journal of the American Dietetic Association.

[19]  G. Keusch,et al.  Evidence for a beneficial effect of plasma exchange in severe active lupus nephritis , 1989 .